Broadfin Capital’s Travere Therapeutics TVTX Stock Holding History

Broadfin Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-150,000	Closed	-$3.01M	–	50
2019 Q2	$3.01M	Buy	+150,000	New	+$2.96M	0.66%	34
2018 Q1	–	Sell	-51,900	Closed	-$1.09M	–	55
2017 Q4	$1.09M	Buy	+51,900	New	+$1.19M	0.18%	40
2015 Q4	–	Sell	-500,000	Closed	-$10.1M	–	94
2015 Q3	$10.1M	Buy	+500,000	New	+$14.8M	0.56%	46
2015 Q2	–	Sell	-500,000	Closed	-$11.2M	–	98
2015 Q1	$11.2M	Buy	+500,000	New	+$7.62M	0.87%	32

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Broadfin Capital's TVTX Position: Q4 2019 in Review

Broadfin Capital sold out of Travere Therapeutics (TVTX) in Q4 2019, closing a stake of 610,414 shares — an estimated $7.08M sold.

Broadfin Capital first reported a position in TVTX in Q1 2014 and held it in 23 quarters. The position peaked at $77.6M in Q3 2016. 131 funds tracked by Wall St. Rank hold TVTX as of Q4 2019.

Broadfin Capital reported no remaining Travere Therapeutics position as of Q4 2019 after selling out during the quarter.
Broadfin Capital sold 610,414 Travere Therapeutics shares in Q4 2019, an estimated $7.08M.
Broadfin Capital first reported a position in Travere Therapeutics in Q1 2014 and held it in 23 quarters.
Broadfin Capital's Travere Therapeutics position peaked at $77.6M in Q3 2016.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.